BCL2 and plasma cell myeloma: For example, miR‐125b‐5p inhibits breast cancer by targeting KIAA1522,16 suppresses esophageal squamous cell carcinoma by regulating HMGA2,26 enhances the chemotherapy sensitivity of gallbladder cancer by downregulating Bcl2,33 and selectively targets IRF4 in multiple myeloma cells.34 In colorectal cancer, it was even reported that CXCL12/CXCR4 axis induced miR‐125b promoted EMT.35 However, in this study, we did not notice the coexpression of miR‐125b with CXCL12/CXCR4 axis in HCC.